Browse the corpus

Ivabradine is an important therapeutic option in the management of stable heart failure, particularly in patients with a left ventricular ejection fraction of 35% or less who remain tachycardic despite guideline-directed therapy. By selectively inhibiting the I(f) current in the sinoatrial node, ivabradine lowers heart rate without affecting myocardial contraction, relaxation, or ventricular repolarization. Because an elevated resting heart rate is strongly associated with adverse cardiovascular outcomes, the appropriate use of ivabradine plays a significant role in reducing hospitalizations related to worsening heart failure. This activity reviews the mechanism of action of ivabradine, its approved and off-label indications, pharmacokinetics, adverse effects, drug-drug interactions, and the clinical evidence supporting its therapeutic role. Key considerations for dosing, contraindications, and monitoring are outlined to promote safe and effective prescribing. The activity also emphasizes the contributions of the interprofessional healthcare team, highlighting the importance of coordinated care, patient education, and timely recognition of bradycardia or arrhythmias. By participating in this activity, clinicians gain essential knowledge and practical strategies to optimize ivabradine therapy, improve treatment decisions, and enhance patient outcomes through its coordinated use within interprofessional care. Objectives: Assess resting heart rate and cardiac rhythm to determine suitability for ivabradine treatment. Identify patients with stable heart failure and reduced ejection fraction who may benefit from ivabradine therapy. Differentiate between contraindications and precautions for ivabradine therapy across diverse patient populations. Collaborate with the interprofessional healthcare team to develop individualized ivabradine treatment plans and ensure coordinated patient monitoring and follow-up. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Ivabradine overdose often presents with severe sinus bradycardia and prolonged periods of asystole, which can be refractory to atropine. Symptoms include a significant reduction in heart rate, with some cases presenting a nadir as low as 15 bpm. The toxicity may be influenced by the severity of the overdose and the individual's serum levels of ivabradine. Additionally, overdose can lead to prolonged sinus node recovery time and QT interval, potentially increasing the risk of arrhythmias, including atrial fibrillation and torsades de pointes. Fatal intoxication has also been reported.[49] Management of Overdose Management of ivabradine overdose focuses on reversing the bradycardia and stabilizing the heart rate. There is no antidote for ivabradine. Intravenous fluids and supportive treatment should be provided. Dopamine and isoproterenol can temporarily increase heart rate, but in some cases, a temporary pacemaker may be necessary to maintain adequate cardiac output.[50][51]

Ivabradine is FDA-approved in the United States for use in patients with symptoms due to stable heart failure and an ejection fraction of 35% or less to reduce their risk of hospital admission for worsening heart failure. An interprofessional team typically manages heart failure, comprising a cardiologist, intensivist, internist, nephrologist, pulmonologist, family medicine specialist, nursing staff, and pharmacist. Healthcare professionals who prescribe ivabradine should monitor their patients' heart rates regularly to ensure optimal treatment. This medication can cause bradycardia, and drug interactions should be kept in mind.[52][53] Cardiologists prescribe ivabradine for heart failure, closely monitoring patient response, particularly heart rate. Pharmacists ensure appropriate dosing, identify potential drug interactions, and provide patient education regarding the proper use and adverse effects of ivabradine. Nurses monitor patients for bradycardia and overall clinical status. Primary care physicians manage comorbidities and collaborate with specialists to ensure proper follow-up. Emergency care physicians are responsible for treating ivabradine overdose or toxicity, focusing on managing bradycardia and potential arrhythmias. Patient education by all healthcare professionals without using medical or technical jargon is essential.[54] A pilot study in long-term care settings for heart failure found that a multimodal interprofessional intervention, including specialist-supported bedside teaching, improved knowledge of heart failure and enhanced collaborative communication. Participants reported increased confidence, clinical proficiency, and more effective interprofessional collaboration. The intervention is feasible and showed a favorable preliminary impact on care processes.[55] An interprofessional team approach and effective communication between all healthcare providers are crucial to minimizing potential adverse effects and enhancing patient outcomes related to ivabradine pharmacotherapy.